7. FUTURE DIRECTIONS
The protocol followed for this study provided many interesting and strong evidences to make important conclusions. However, we found still there is a scope for the improvement to this protocol in order to elucidate the results and which can be extrapolated to human beings. The lack of advanced technical resources and ethical issues inhibits us to conduct some of the experiments. As a part of additional work needed for the present formulation, following can be made and which would probably make the formulation an eligible advanced drug delivery system for human use.

- Alternative *in vitro* release model is to be developed to have better correlation between *in vitro* and *in vivo* drug release kinetics. The model followed does not simulate the physiologic conditions upon intravenous administration.
- The stability of the formulation is to be evaluated elaborately. It would be necessary to lyophilize the product to get better picture of the shelf life.
- Sterilization process for liposome should be established without affecting the stability.
- The *in vivo* studies are to be repeated with more number of animals and for different batches of liposomes. Evaluation in non-rodent (dog or rabbit) species is also advisable to have better understanding of the behaviour of the *in vivo* drug delivery system.
- Anticancer efficacy of the formulation needs to be evaluated.